IBD: Drug treatment monitoring can improve retention of anti-tumor necrosis factor alpha drugs in pediatric crohn's disease.

In recent years, therapeutic drug monitoring (TDM) of anti-tumor necrosis factor alpha (anti-TNF alpha) has been widely used.
study to study its effects on long-term drug retention and clinical outcomes in pediatric patients with Crohn's disease (CD).
method researchers reviewed the medical records of pediatric CD patients who received anti-TNf alpha therapy from 2007 to 2018.
patients were divided into patients who started anti-TNf alpha treatment between 2007 and 2012 (when there was no TDM-) and between 2013 and 2018 patients who began to do so with TNF alpha, with the age of TDM (TDM plus).
the main outcome indicators include the time of termination of treatment with the first anti-TNf alpha (drug retention), recurrence and the hospitalization rate and surgical excision rate of the first anti-TNf alpha treatment each year.
results This study included 197 patients (n s 98, TDM-; n s 99, TDM plus).
longer drug retention in the TDM group than in the TDM-group (45.0 x 2.7 vs 33.5 to 2.4 months; P-0.001), lower annual hospitalization rate per patient (0.51-0.7 vs. 0.92-0.81;P-lt.001) and higher treatment enhancement (70%18.;P. There was no significant difference in the rate of surgical excision
.
the analysis of the entire queue, Adamu monoabandalation and inflis monoabinomination were retained for longer periods of time (45.3 x 2.8 vs 34.8 x 2.5 months; P s 0.007).
Conclusion that TDM-based treatment can extend drug retention time, thereby making better use of anti-TNf alpha drugs, with other beneficial results.
.